This website uses cookies
Read our Privacy policy and Terms of use for more information.
Apr 21, 2026
Psychedelics get the fast lane, peptides stir controversy, and Lilly's $7B CAR-T deal.
Apr 16, 2026
Novo bets big on AI, pharma earnings season is here, and M&A is surging. Biotech is anything but quiet right now.
Apr 14, 2026
One CAR-T therapy, three diseases gone. Plus: biotech’s next trillion-dollar molecule.
Apr 9, 2026
FDA pushes for stronger ad oversight, Gilead continues its deal spree, and a two-person AI startup sparks controversy with $1.8B projections.
Apr 7, 2026
Pharma tariffs shake the market, Anthropic drops $400M on biotech, and a Lilly vs. Novo deep dive
Apr 2, 2026
GLP-1 pill wars heat up, billion-dollar deals fly, and the FDA faces a stacked Q2
Mar 31, 2026
ACIP chaos, Lilly’s $2.75B AI bet, and a biotech policy fight that’s heating up fast.
Mar 19, 2026
This story and more in the March 19, 2026 issue
Mar 17, 2026
This story and more in the March 17, 2026 issue
